The MIPS study showed that adults with type 2 diabetes using WellDoc’s software achieved a 2.03-point reduction in A1c, an indicator used to identify the average blood glucose level of a diabetic over a 12-week time period. Every one-point drop reduces the risk of diabetes complications (e.g., amputations, blindness) by as much as 40 percent. The top ten diabetes drugs in the U.S., on average, reduce A1c by about one point. The results of this trial were published in Diabetes Technologies and Therapeutics, Volume 10, 2008.

Quinn then conducted the first, one-year randomized controlled trial (RCT) of a mobile phone-based diabetes coaching and decision support intervention. The results of this study were published in the September, 2011 edition (Volume 34, Number 9) of Diabetes Care, the world’s preeminent diabetes-focused scientific journal, published by the American Diabetes Association. The trial met its primary endpoint of reducing blood glucose levels over one year, demonstrating that patients using the WellDoc system, plus their usual care, had an average decline in A1c of 1.9 percentage points compared to a 0.7-percentage-point decline seen among patients treated with usual care alone (control group).

WellDoc became one of the first mobile health (mHealth) solutions to receive United States FDA 510(k) clearance to market its software product as a class II medical device for health care providers and their adult patients with type 2 diabetes.

The company entered the Emerging Technology Center (ETC), won a national award from the National Business Incubation Association for best incubator company of the year, and now has 65 employees, with offices in Columbia, Md., Wilmington, Del., and Bangalore, India.

RioRey received $5 million in venture funding in 2006 and is a leading provider of protection against distributed denial of service attacks.

The MIPS project helped Valortim progress to a Phase I clinical trial. PharmAthene received over $27 million in government funding for the advanced development of Valortim.

The MIPS project enabled initial proof of concept for the underlying technology. As a result of the project, GL-2045 advanced in preclinical development. The product to be commercialized, GL-2045, is a recombinant IgG1 Fc fusion protein that multimerizes yet retains full Fc functionality, presenting polyvalent Fc to more than one Fc receptor simultaneously. IVIG is indicated for numerous autoimmune diseases, including chronic inflammatory demyelinating polyneuropathy, a peripheral nerve disease, and idiopathic thrombocytopenic purpura, a bleeding disorder in which the immune system destroys platelets. GL-2045 is anticipated to be developed in these types of autoimmune diseases. Because IVIG has been used for decades, its efficacy and safety are well established, decreasing the riskiness of GL-2045 compared to a novel recombinant drug candidate that does not have a predecessor blood product.

In October, 2011, the National Cancer Institute (NCI) awarded the company a Small Business Innovation Research (SBIR) Phase II contract for up to $1.5 million. With the funding, Gliknik advanced its lead compounds from its first-in-class Stradobody™ platform towards the clinic. In October, 2012, the company raised $4.9 million in Series B Financing, supported by Baxter Ventures, LifeTech Development Partners, Brace Pharma, and the Maryland Health Care Product Development Corporation. In September, 2013, Gliknik announced a significant license of GL-2045 to Pfizer Inc. Pfizer has received orphan drug status from the FDA for the development of the product. Gliknik received an upfront payment of $25 million and is eligible to receive development, regulatory and commercial milestone payments.

Gliknik also has a peptide cancer drug, GL-0817, currently enrolling a Phase IIb clinical study in seven countries for oral cavity cancer. Gliknik is conducting research on numerous drug candidates from its Stradomer™ technology platform.

This MIPS project enabled Green Eyes to commercialize ProbeGuard, which reduces servicing costs by 50-75 percent while improving data quality. The system also allows real-time access to data.

The MIPS study showed that adults with type 2 diabetes using WellDoc’s software achieved a 2.03-point reduction in A1c, an indicator used to identify the average blood glucose level of a diabetic over a 12-week time period. Every one-point drop reduces the risk of diabetes complications (e.g., amputations, blindness) by as much as 40 percent. The top ten diabetes drugs in the U.S., on average, reduce A1c by about one point. The results of this trial were published in Diabetes Technologies and Therapeutics, Volume 10, 2008.

Quinn then conducted the first, one-year randomized controlled trial (RCT) of a mobile phone-based diabetes coaching and decision support intervention. The results of this study were published in the September, 2011 edition (Volume 34, Number 9) of Diabetes Care, the world’s preeminent diabetes-focused scientific journal, published by the American Diabetes Association. The trial met its primary endpoint of reducing blood glucose levels over one year, demonstrating that patients using the WellDoc system, plus their usual care, had an average decline in A1c of 1.9 percentage points compared to a 0.7-percentage-point decline seen among patients treated with usual care alone (control group).

WellDoc became one of the first mobile health (mHealth) solutions to receive United States FDA 510(k) clearance to market its software product as a class II medical device for health care providers and their adult patients with type 2 diabetes.

The company entered the Emerging Technology Center (ETC), won a national award from the National Business Incubation Association for best incubator company of the year, and now has 65 employees, with offices in Columbia, Md., Wilmington, Del., and Bangalore, India.